Opinion|Videos|May 30, 2024
Aligning With 2023 ESC Guidelines in oHCM Treatment
Author(s)Anjali Tiku Owens, MD
Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023.
Advertisement
Episodes in this series
- Where do cardiac myosin inhibitors fit into the treatment plans of your patients with oHMC, according to the most recent guidelines?
ESC Guidelines 2023
- Initiating cardiac myosin inhibitors earlier?
- Use in patients who are severely symptomatic?
- MAPLE-HCM trial
Advertisement
Related to this article
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Finerenone Outperforms Spironolactone, Eplerenone in HFpEF, HFmrEF Renal Outcomes
3
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
4
Hidradenitis Suppurativa Care: Expectations, Comorbidities, and Wound Care
5